Abstracts tagged "health care cost and spondylarthritis"

Abstract Number: 1243 • 2016 ACR/ARHP Annual Meeting
Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis
Cécile Gaujoux-Viala¹, Laure Gossec², Christel Castelli³, Cédric Lukas⁴, Françoise Barchechath-Flaisler⁵, Jean-Pierre Daures⁶ and Maxime Dougados⁷, ¹Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Nîmes University Hospital, Rheumatology Department, Nimes, France, ⁶EA2415, Nîmes, France, ⁷Paris Descartes University, Paris, France
Background/Purpose: The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures…
Abstract Number: 1688 • 2015 ACR/ARHP Annual Meeting
Trends in Hospitalizations and Charges for Ankylosing Spondylitis, 1993-2012
Na Lu¹, Hyon Choi² and Maureen Dubreuil^3,4, ¹Boston University School of Medicine, Boston, MA, ²Massachussetts General Hospital/Harvard Medical School, Boston, MA, ³Rheumatology, Boston VA HealthCare System, Boston, MA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: In the last two decades, tumor necrosis factor alpha (TNFα) inhibitors have been approved for use, and recommended as part of clinical treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].